Orthocresol

Orthocresol

SCHEMBL4085176

CCCCC(=O)O.Cc1ccccc1O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
AKR1B1 P15121 1/20 0.47
ALDH1A1 P00352 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
GPR84 Q9NQS5 7/20 0.45
PPARG P37231 7/20 0.45
PPARD Q03181 7/20 0.45
PPARA Q07869 7/20 0.45
HDAC11 Q96DB2 6/20 0.45
TSHR P16473 4/20 0.45
PTPN1 P18031 3/20 0.45
TLR2 O60603 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
FABP4 P15090 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexanoate SCHEMBL8539398 0.95 AKR1B1 (0.55) CES2CES1AKR1B1ALDH1A1GPR84
Orthocresol SCHEMBL1900384 0.89 FFAR3 (0.50) CES2CES1AKR1B1ALDH1A1MEN1
O-Xylene SCHEMBL28841744 0.89 AKR1B1 (0.54) CES2CES1AKR1B1ALDH1A1GPR84
Hexanoate SCHEMBL5013710 0.83 AKR1B1 (0.64) CES2CES1AKR1B1ALDH1A1GPR84
Orthocresol SCHEMBL11464146 0.83 AKR1B1 (0.48) CES2CES1AKR1B1ALDH1A1CYP1A2
Orthocresol SCHEMBL27373848 0.82 ESR1 (0.47) ALDH1A1CYP1A2CYP2C19TSHRTDP1
Octanoic Acid SCHEMBL9716530 0.81 GPR84 (0.65) CES2CES1AKR1B1ALDH1A1CYP1A2
Stearic Acid SCHEMBL11803277 0.81 GPR84 (0.65) CES2CES1AKR1B1ALDH1A1CYP1A2
Heptanoate SCHEMBL6704869 0.81 GPR84 (0.65) CES2CES1AKR1B1ALDH1A1CYP1A2
Decanoic Acid SCHEMBL28136495 0.81 GPR84 (0.65) CES2CES1AKR1B1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012017204-A1 EFFICIENT AND COST-EFFECTIVE PROCESS FOR THE MANUFACTURE OF AMYL M-CRESOL AESICA PHARMACEUTICALS LIMITED (GB) 2012-02-09 WO claimed
WO-2012017204-A1 EFFICIENT AND COST-EFFECTIVE PROCESS FOR THE MANUFACTURE OF AMYL M-CRESOL AESICA PHARMACEUTICALS LIMITED (GB) 2012-02-09 WO disclosed
WO-2012017204-A1 EFFICIENT AND COST-EFFECTIVE PROCESS FOR THE MANUFACTURE OF AMYL M-CRESOL AESICA PHARMACEUTICALS LIMITED (GB) 2012-02-09 WO disclosed
US-20090186138-A1 Method of Flavoring GIVAUDAN SA (CH) 2009-07-23 US disclosed
US-4230624-A CYCLIZATION, BASIC CATALYSTS AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (FR) 1980-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186138-A1 Method of Flavoring TAS2R5, TAS2R50, TAS2R10 CES2 1164/4885CES1 1532/4885AKR1B1 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.